
Biomodifying
In-licensed anti MUC-1 antibodies targeting several cancers

Bioproject
In-licensed Vibozilimod for treatment of auto-immune disorders

InStem
To identify inhibitors of a novel target to address PARP resistance in solid tumours

University Of Michigan
To evaluate anti-MUC-1 ADC in preclinical models

Scripps Research
To investigate the effect of SPARC NCEs on modulating autophagy and inflammasome

Sun Pharma
Out-licensed Xelpros, Vibozilimod and Sezaby

Tripoint Therapeutics
Out-licensed Elepsia 1000mg and 1500mg

UK Dementia Research Institute
To identify targets and potential modulators of proteotoxicity in Alzheimer’s Disease

Visiox
Out-licensed Brimonidine and Difluprednate

Washington University
To study Abl kinase inhibitors in models of neurodegeneration